Skip to main content

Bernard Escudier

Contact

address:

Institut Gustave Roussy, Villejuif, France

Dr Bernard Escudier is head of the French Group of Immunotherapy and the chairman of the GU tumor board at Gustave Roussy Institute in Villejuif, France.

Dr Escudier trained in Paris. He received his MD in 1981 as a cardiologist, and moved to Gustave Roussy Institute in 1983, initially in the Intensive Care Unit, and then took the lead of the Immunotherapy Unit, mainly in charge of developing programs in renal cell carcinoma and in melanoma.

His largest fields of interest are renal cell carcinoma, immunotherapy (cytokines, vaccines), and development of new strategies (antiangiogenic drugs, gene therapy). He has been largely involved in the development of new targeted therapies for RCC, and has been the PI of many trials in the field of RCC, from phase I to phase III.

He is a member of ASCO, AACR, ESMO, and has been the chair of the GU Group of ESMO from 2008 to 2010, and is currently the ESMO faculty coordinator for the GU group. He has published more than 290 papers in peer reviewed journals, mainly in the field of Renal Cancer.

print
PRINT

Latest contributions from Bernard Escudier

Expert discussion: Metastatic RCC updates from ASCO GU 2020

25-02-2020 | Renal cell carcinoma | Conference coverage | Video

Metastatic RCC updates from ASCO GU 2020

Bernard Escudier and Viktor Grünwald take us through the metastatic renal cell carcinoma studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib.

This independent video was supported by an educational grant from Pfizer and Merck KGaA.